Onco Actu du 24 septembre 2018

	2. Etiologie
Valsartan: review of impurities extended to other sartan medicines [EMA] A batch of losartan found to contain low levels of NDEA.
	2.7 Etiologie - Obésité
Obesity to overtake smoking as top cause of cancer in women [The Telegraph] The crossover point will be reached in 2043 among the female population, the report concluded.
How we estimated when obesity might catch smoking as the top cause of cancer [Cancer Research UK] If these trends in the number of cases caused by these risk factors continue, overweight and obesity could overtake smoking as the biggest preventable cause of cancer in women by 2043.
	3.1 Prévention - Tabac
Stoptober: Just 1 in 10 will be smokers in five years' time, says PHE [Cancer Research UK] New figures, released at the launch of PHE’s annual stop smoking campaign Stoptober, show the number of smokers in England has fallen by more than a million since 2014.
	3.1.1 Prévention - Tabac - e-cigs
E-cigarettes are almost certainly better than smoking [The Economist] Unlike ordinary cigarettes, which rely on burning tobacco to deliver their payload, e-cigarettes use an electric charge to vaporise a dose of nicotine (accompanied, often, by various flavouring chemicals). They have proved extremely popular, particularly in America, Britain and Japan.
	4.12 Biopsies liquides
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid [Roche] Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability.
With new blood test, Roche dives deeper into personal cancer care [Reuters] The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient’s tumor.
	4.2 Dép., diag. & prono. - Génome
Raising Awareness of BRCA Mutations [NY Times] Genetic testing may help those at high risk take steps to prevent deadly cancers.
Solving the genome puzzle [The Guardian] With advances in gene technology helping to diagnose very rare diseases, has the new era of personalised medicine finally arrived?
	5. Traitements
Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments [NCI] “We’re not paying enough attention to the other forms of cardiovascular toxicities from cancer drugs beyond doxorubicin,” Dr. Moslehi continued, referring to the commonly used chemotherapy drug that has been the focus of much cardiotoxicity research over the past decade. “We need to have a broader perspective.”
	5.10 Traitements - Essais
How one pharmaceutical company is reinventing the clinical trial [STAT] People are hungry for personal health data. This isn’t breaking news. But until now, sharing data with clinical trial participants hasn’t been standard operating procedure.
FDA proposes stiff fines for failing to report clinical trials [Nature] Pharmaceutical companies could face penalties of up to US$10,000 per day.
Reporting Clinical Trials [In the Pipeline] The take-home from both studies is that most clinical trials (in both the US and EU) are now obliged to report data within a year of finishing. Many trial sponsors seem to be having trouble making that deadline, and so far the problem seems to be worse in the EU. And on both sides of the Atlantic, it’s the drug-industry trials that have a far better compliance rate compared to the academic ones.
	5.12.1 Immunothérapies - partenariats
Agenus sells cut of Incyte, Merck milestone streams [FierceBiotech] The deal comes as Agenus seeks to keep its pipeline of immuno-oncology candidates moving forward while attracting partners for the assets.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
Parker collaborator Tessa allies with St. Jude, launches a new T cell program for pediatric brain cancer [EndPoints] Tessa wants to show how its preclinical program using CAR-expressing Virus-Specific T cells — or VSTs — could change that prognosis, hoping to advance therapies that would trigger a more durable response.
	5.12.4 Immunothérapies - Essais
Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain [NCI] Results from a clinical trial show that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors in more than half of participants with melanoma that had spread to the brain.
	5.13 WCLC
Comprehensive Genomic Profiling Aids in the Identification of Personalized Therapeutic Options [IASLC] A retrospective analysis was performed on the results of CGP collected from 46 patients with a cancer diagnosis utilizing Foundation Medicine’s FoundationOne® technology over a three-year period.
Survey Data from Lung Cancer Alliance Highlights the Unmet Emotional Needs of Long-Term Lung Cancer Survivors [IASLC] LCA conducted a 122 question, online survey on treatment and smoking histories of the respondents. Of the 820 participants, 471 self-identified as lung cancer patients or survivors and 349 self-identified as caregivers or loved ones of lung cancer patients or survivors.
Oncogene-Driven Patient-Caregiver Communities Creating New Paradigm for Non-Small Cell Lung Cancer Research [IASLC] The communities, formed by patients and caregivers dealing with cancers driven by these oncogenes, use a variety of tools for education and support including Facebook groups, websites, newsletters, social media and blogs, and provide information about treatments, common experiences, tips from clinicians and real-life connections.
	5.2.1 Pharma - Partenariats
Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts [EndPoints] Back when OncoMed signed up with Celgene, its shares were trading at more than $29. This morning it will start trading at about 10% of that figure, with a much diminished market cap of $107 million. The bispecific is in a Phase Ib study for patients with ovarian cancer, and OncoMed expects to offer some preliminary data at ESMO in October.
	5.2.3 Pharma - économie
Y-mAbs Upsizes IPO, Gets $96M to Test Two Pediatric Cancer Drugs [Xconomy] Two Y-mAbs antibody drugs are in clinical development for neuroblastoma. The first, naxitamab, targets a molecule on the surface of tumors called GD2.
Ron DePinho raises seed cash for MD Anderson colleague’s work on a ‘Holy Grail molecule’ in cancer, inflammation [EndPoints] Given that hyperactivated STAT3 is present in more than 50% of cancers — often turning up immunosuppression in the tumor microenvironment — David Tweardy theorized that a potent inhibitor here that doesn’t trigger safety issues could have a big impact.
	5.3.4 Traitements - AMM (FDA, EMA,...)
AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy [AbbVie] If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma [Exelixis] In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit.
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib [Takeda] Opinion Based on Pivotal Phase 2 ALTA Trial, in which ALUNBRIG Demonstrated an Objective Response Rate of 56% and Longest Reported Median Progression-Free Survival of 16.7 months in the Post-Crizotinib Setting.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018 [EMA] The CHMP recommended granting marketing authorisations for two cancer medicines: Alunbrig (brigatinib), for the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, and Apealea (paclitaxel), for the treatment of ovarian cancer.
Takeda lung cancer drug gets European panel nod [Reuters] Alunbrig was approved last year by the U.S. Food and Drug Administration as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer drug crizotinib, the standard initial treatment for the disease.
	5.6 ESMO
ESMO Launches New Patient Guide in Cervical Cancer [ESMO] A fully updated new edition delivers reliable, comprehensive information for patients.
	6. Lutte contre les cancers
At Joe Biden's Urging, Airbnb, WeWork, And Others Commit To Help Cancer Patients [Forbes] Like many of the commitments being made at the Biden Cancer Summit, it's not an Earth-shaking change, certainly not a cure. It's kind of a Ronald McDonald House for the future. But it could make a big difference to the families of people with cancer, who often have to figure out how to stay at treatment centers that can be far from home.
Biden pushes for progress at cancer summit [Washington Post] The former vice president convenes a national meeting to continue the "cancer moonshot" work.
	6.1 Observation
Global push to cut deaths from cancer and heart disease wildly off course [The Guardian] Lack of progress in reducing early deaths from chronic diseases could cause majority of UN member states to miss 2030 deadline.
Drugs, Alcohol and Suicide Are Killing So Many Young Americans That the Country’s Average Lifespan Is Falling [Time] Deaths from heart disease and cancer, the top two killers of adults older than 65, both declined, as did those from strokes.
	6.7 DMP, Big Data & applis
Dimensions Partners With Reprints Desk To Provide Intelligent Citation References and Journal Article Stats [Dimensions] Reprints Desk’s award-winning Article Galaxy research platform provides customers with fast, reliable, and personalized access to full-text scientific literature and intelligent data insights. Digital Science’s new research and discovery tool, Dimensions, integrates more than 137 million publications, grants, clinical trials, patents, and policy documents.
	6.9 Controverses
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar [NY Times] The company, Paige.AI, is one in a burgeoning field of start-ups that are applying artificial intelligence to health care, yet it has an advantage over many competitors: The company has an exclusive deal to use the cancer center’s vast archive of 25 million patient tissue slides, along with decades of work by its world-renowned pathologists.
Statement from Cochrane's Governing Board [Cochrane] It is about a long-term pattern of behaviour that we say is totally, and utterly, at variance with the principles and governance of the Cochrane Collaboration. This is about integrity, accountability and leadership.